Call Us + 33 1 84 88 31 00

Article R5121-51-3 of the French Public Health Code

To obtain a marketing authorisation in France and in at least one other Member State of the European Community or party to the Agreement on the European Economic Area, for a medicinal product which is authorised neither in the European Community nor in the European Economic Area, the applicant must submit a marketing authorisation application to the Director General of the Agence nationale de sécurité du médicament et des produits…

Read More »

Article R5121-51-4 of the French Public Health Code

In the event of agreement within the coordination group, referred to by the Director General of the Agence nationale de sécurité du médicament et des produits de santé or by another State : 1° In the case provided for in Article R. 5121-51-1, the Director General of the Agency will notify the States concerned and the marketing authorisation holder of the agreement. In accordance with the assessment report thus approved,…

Read More »

Article R5121-51-5 of the French Public Health Code

In the absence of agreement within the coordination group, the Community arbitration procedure provided for in articles 32 to 34 of Directive 2001/83/EC of the European Parliament and of the Council applies. Where France is the reference State, the Director General of the Agence nationale de sécurité du médicament et des produits de santé is responsible for initiating this procedure by informing the European Medicines Agency of the disagreement. The…

Read More »

Article R5121-51-6 of the French Public Health Code

At the end of the procedures provided for in this sub-section, the marketing authorisation is issued or varied by the Director General of the Agence nationale de sécurité du médicament et des produits de santé within thirty days of notification of the agreement by the reference State or by the European Commission, subject to the applicant providing a French translation of the summary of product characteristics, the package leaflet and…

Read More »

Article R5121-51-7 of the French Public Health Code

Articles R. 5121-51 to R. 5121-51-4 are applicable to homeopathic medicinal products subject to the registration referred to in article L. 5121-13. This sub-section does not apply to homeopathic medicinal products subject to the marketing authorisation referred to in article L. 5121-8.

Read More »

Article R5121-51-8 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé or the applicant for marketing authorisation may refer the matter to the European Medicines Agency with a view to the application of the Community arbitration procedure provided for in Articles 32 to 34 of Directive 2001/83/EC of the European Parliament and of the Council when divergent decisions concerning the authorisation, variation, suspension or withdrawal…

Read More »

Article R5121-51-9 of the French Public Health Code

In specific cases of interest to the European Union, the Director General of the National Agency for the Safety of Medicines and Health Products or the applicant shall refer the matter to the European Medicines Agency for application of the Community arbitration procedure before a decision is taken on the granting, variation, suspension or withdrawal of the marketing authorisation. The Director General of the Agence nationale de sécurité du médicament…

Read More »

Article R5121-51-11 of the French Public Health Code

At the end of the Community arbitration procedure implemented in accordance with the provisions of Articles R. 5121-51-8 and R. 5121-51-9, the Director General of the Agence nationale de sécurité du médicament et des produits de santé shall grant, vary, suspend or revoke the marketing authorisation within a period of thirty days, in accordance with the decision taken by the European Commission at the end of this procedure.

Read More »

Article R5121-51-12 of the French Public Health Code

Each year, the Director General of the Agence nationale de sécurité du médicament et des produits de santé sends the coordination group referred to in Article 27 of Directive 2001/83/EC of the European Parliament and of the Council a list of medicinal products for which he considers it necessary to harmonise the summaries of product characteristics.

Read More »

Article R5121-53 of the French Public Health Code

Where a marketing authorisation issued by the European Union pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency provides that the medicinal product is subject to prescription, the Director General of the Agence nationale de sécurité du médicament…

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.